Literature DB >> 9747884

DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site.

J P Blaydes1, T R Hupp.   

Abstract

The sequence-specific DNA binding activity of p53 is negatively regulated by a C-terminal domain whose phosphorylation in vitro can activate the latent DNA binding function of the protein. The DNA binding activity of p53 is a core component of its stress-activated transcription function, yet it is not yet clear whether phosphorylation within the C-terminal domain plays a role in the p53 damage response in vivo. As the casein kinase 2 (CK2) site at serine 392 is the C-terminal phosphorylation motif that exhibits the most pronounced conservation at the primary amino acid level, we have focused on determining whether the CK2 site is modified in vivo and whether radiation effects the extent of that phosphorylation. Using antibodies that can detect serine 392-phosphorylation of p53, we demonstrate that UV radiation can trigger extensive phosphorylation at the CK2 site. The CK2 inhibitor, 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB), can partially inhibit the UV-induced phosphorylation at serine 392, suggesting that CK2 is one of the major serine 392-kinases. However, a striking increase in UV-induced serine 392 phosphorylation and p53 transactivation function at higher levels of DRB suggests that a DRB-resistant/stress-activated pathway may target serine 392 in vivo. These data demonstrate that radiation-induced phosphorylation of p53 can occur in vivo at serine 392 and implicate a CK2-independent signal cascade that can function to modulate serine 392 phosphorylation in cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9747884     DOI: 10.1038/sj.onc.1202014

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  43 in total

1.  Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage.

Authors:  N H Chehab; A Malikzay; E S Stavridi; T D Halazonetis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage.

Authors:  K Webley; J A Bond; C J Jones; J P Blaydes; A Craig; T Hupp; D Wynford-Thomas
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

Review 3.  Protein kinase CK2: structure, regulation and role in cellular decisions of life and death.

Authors:  David W Litchfield
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

4.  DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulation.

Authors:  Olga Moiseeva; Frédérick A Mallette; Utpal K Mukhopadhyay; Adrian Moores; Gerardo Ferbeyre
Journal:  Mol Biol Cell       Date:  2006-01-25       Impact factor: 4.138

5.  Functional phosphorylation sites in the C-terminal region of the multivalent multifunctional transcriptional factor CTCF.

Authors:  E M Klenova; I V Chernukhin; A El-Kady; R E Lee; E M Pugacheva; D I Loukinov; G H Goodwin; D Delgado; G N Filippova; J León; H C Morse; P E Neiman; V V Lobanenkov
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

6.  The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway.

Authors:  Nicola J Maclaine; Ted R Hupp
Journal:  Aging (Albany NY)       Date:  2009-05-07       Impact factor: 5.682

7.  Expression of CtBP family protein isoforms in breast cancer and their role in chemoresistance.

Authors:  Charles N Birts; Rachael Harding; Gehan Soosaipillai; Trisha Halder; Ali Azim-Araghi; Matthew Darley; Ramsey I Cutress; Adrian C Bateman; Jeremy P Blaydes
Journal:  Biol Cell       Date:  2010-01       Impact factor: 4.458

8.  The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12.

Authors:  Eva Roubalová; Veronika Kvardová; Roman Hrstka; Sárka Borilová; Eva Michalová; Lenka Dubská; Petr Müller; Petr Sova; Borivoj Vojtesek
Journal:  Invest New Drugs       Date:  2009-06-05       Impact factor: 3.850

9.  AGR2 oncoprotein inhibits p38 MAPK and p53 activation through a DUSP10-mediated regulatory pathway.

Authors:  Roman Hrstka; Pavla Bouchalova; Eva Michalova; Eva Matoulkova; Petr Muller; Philip J Coates; Borivoj Vojtesek
Journal:  Mol Oncol       Date:  2015-12-17       Impact factor: 6.603

10.  Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.

Authors:  Sonia Lain; Jonathan J Hollick; Johanna Campbell; Oliver D Staples; Maureen Higgins; Mustapha Aoubala; Anna McCarthy; Virginia Appleyard; Karen E Murray; Lee Baker; Alastair Thompson; Joanne Mathers; Stephen J Holland; Michael J R Stark; Georgia Pass; Julie Woods; David P Lane; Nicholas J Westwood
Journal:  Cancer Cell       Date:  2008-05       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.